EORTC abstracts selected at EBCC-12 Virtual Congress

3 EORTC abstracts were selected for the 12th European Breast Cancer Conference (EBCC-12) that will take place virtually on 2-3 October 2020.

Plenary Session

Keynote Lecture, Best and Late Breaking Abstract Presentations

Clinical Utility of MammaPrint testing in Invasive Lobular Carcinoma: Results from the MINDACT phase III trial

  • Presentation number: ORAL-007
  • Date: 2 October 2020, 13:50-14:00
  • Speaker: Otto Metzger (USA)

Proffered Papers Session

Updated results of the MINDACT trial: 70-gene signature to guide de-escalation of chemotherapy in early breast cancer

  • Presentation number: ORAL-021
  • Date: 3 October 2020, 13:00-13:10
  • Speaker: Emiel Rutgers (The Netherlands)

Screen-detected breast cancers have different tumor biology and better prognosis compared to interval breast cancers

EBCC-12 is a breast cancer conference where the very latest practice-changing research is presented. It aims to provide a unique multidisciplinary setting for all professionals with a common interest in breast cancer to discuss, debate, inform and educate themselves about this evolving disease.

To view the full two day programme, visit the EBCC-12 searchable programme.

Registration for the virtual event is still open. For further information click here.

Back to news list

Related News

  • EORTC strategic meeting with Middle Eastern Ambassadors

  • EORTC Quality of Life Group projects to be presented at ISOQOL 2023

  • Celebrating Sarcoma Awareness Month with the start of EU-funded STREXIT 2 project study

  • “Best Proposal in Medicine” award received by EORTC at the PTCOG 61 Conference

  • Long-term efficacy and safety outcomes of the EORTC/LYSA/FIL H10 trial assessing early PET-scan adapted treatment of limited stage Hodgkin lymphoma

  • Joint Statement: health organisations define EHDS’ opt out required for life saving research

  • Congratulations to Dr. Hans Wildiers, winner of the B.J. Kennedy Geriatric Oncology Award

  • Full validation of the EORTC CAT Core

  • SISAQOL-IMI: Setting standards for the use of patient-reported outcome data in cancer trials

  • Synthesis of minimally important differences for interpreting EORTC QLQ-C30 change scores across nine cancer types